Graphical Abstract
![](https://wqketang.oss-cn-beijing.aliyuncs.com/zip-unzip/zip-468520c7-6c3d-4120-9ee5-0757d834a6ef/iliver-3-2-100098/files/iliver-3-2-100098-FE1.jpg?Expires=1725756076&OSSAccessKeyId=STS.NT5eViCkqzTYdbfdqxMkjpyyq&Signature=ta3g6CcApx%2FMzR4E%2BpLUT2utKN8%3D&security-token=CAISywJ1q6Ft5B2yfSjIr5eALuzdrrRQzZayZkTXgHEtQeRGn7zSkzz2IHtKenhsBOsbtfk1mG5W5%2FgZlqJ9SptIAEfJa9d99MzUP%2FpFltCT1fau5Jko1beHewHKeTOZsebWZ%2BLmNqC%2FHt6md1HDkAJq3LL%2Bbk%2FMdle5MJqP%2B%2FUFB5ZtKWveVzddA8pMLQZPsdITMWCrVcygKRn3mGHdfiEK00he8TouufTinpHMskGA1Aell7Mvyt6vcsT%2BXa5FJ4xiVtq55utye5fa3TRYgxowr%2Fwo0v0YpGya5YzHXwcPskvdKZbo78UqLQlla6w%2BGqFJqvPxr%2Fp8t%2Fx5fWJKAezhVgs8cVM8JOjIqKOscIsiJsO71SmqFV55c8Fdm%2BgUooJVgIMhTnduUfAPJAGOxzJitP%2BUVGGphr60TEnBL4rB5MUctfzRp75SXVPUTzDnGoABjuNLcf76FQN6p3t%2BSlCg%2FxR5C72RIk78k%2BUi44L9ZBmFT6F8GV7aXA52D1Ps56knKF6PAnhRivwyTxgsolycBfvccb3t5jGJ24SgY0aYosAECutxAo7sJhSwlwZvGwGDZJsop1vGiZ8eN1MbtZeRRuMeaZ2I%2BQo%2BnVP6Cf%2F0pDsgAA%3D%3D)
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
The ASAP and GALAD scores are widely used diagnostic models for detecting hepatocellular carcinoma (HCC), incorporating factors such as sex, age, alpha-fetoprotein (AFP), protein induced by vitamin K absence or antagonist-Ⅱ (PIVKA-Ⅱ), and lens culinaris agglutinin-reactive fraction of AFP (AFP-L3%). This study compares the diagnostic efficacy of the ASAP and GALAD scores in the early detection of HCC in patients with non-alcoholic fatty liver disease (NAFLD).
NAFLD patients with and without HCC were recruited from 12 Chinese tertiary hospitals. Serum levels of AFP, PIVKA-Ⅱ, and AFP-L3% were measured. The diagnostic accuracy of individual biomarkers, the ASAP score, and the GALAD score in detecting NAFLD-HCC at various stages was evaluated using receiver operating characteristic (ROC) curves and area under the curve (AUC) values.
In a cohort of 147 NAFLD-HCC cases and 460 NAFLD controls, both the ASAP and GALAD scores outperformed individual biomarkers in detecting NAFLD-HCC. The ASAP score demonstrated a high AUC of 0.910 (sensitivity: 80.3%, specificity: 92.8%) for identifying NAFLD-HCC at all stages, surpassing AFP (AUC: 0.716, P < 0.001), PIVKA-Ⅱ (AUC: 0.849, P < 0.001), AFP-L3% (AUC: 0.663, P < 0.001), and the GALAD score (AUC: 0.882, P = 0.014). Comparable results were observed for early-stage NAFLD-HCC and for detecting HCC in NAFLD patients with or without cirrhosis.
The ASAP score, which excludes the AFP-L3% indicator, demonstrated superior performance in differentiating NAFLD-HCC compared to the GALAD score, suggesting its potential for early screening of HCC in NAFLD patients.
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-22. https://doi.org/10.1016/S0140-6736(20)30925-9.
Nakatsuka T, Tateishi R, Koike K. Changing clinical management of NAFLD in Asia. Liver Int 2022;42(9):1955-68. https://doi.org/10.1111/liv.15046.
Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019:a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2019;4(5):389-98. https://doi.org/10.1016/S2468-1253(19)30039-1.
Liu J, Tian Y, Fu X, et al. Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis. Chin Med J 2022;135(14):1682-91. https://doi.org/10.1097/CM9.0000000000002277.
Ioannou GN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol 2021;75(6):1476-84. https://doi.org/10.1016/j.jhep.2021.08.012.
Foerster F, Gairing SJ, Muller L, et al. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol 2022;76(2):446-57. https://doi.org/10.1016/j.jhep.2021.09.007.
Seif El Dahan K, Daher D, Singal AG. HCC Surveillance in Patients with NAFLD. Clin Mol Hepatol. 2023;29(Suppl):S207-19. https://doi.org/10.3350/cmh.2022.0247.
Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015;62(6):1723-30. https://doi.org/10.1002/hep.28123.
Pais R, Fartoux L, Goumard C, et al. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period. Aliment Pharmacol Ther 2017;46(9):856-63. https://doi.org/10.1111/apt.14261.
Guan MC, Wang MD, Liu SY, et al. Early diagnosis and therapeutic strategies for hepatocellular carcinoma: From bench to bedside. World J Gastrointest Oncol 2021;13(4):197-215. https://doi.org/10.4251/wjgo.v13.i4.197.
Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67(1):358-80. https://doi.org/10.1002/hep.29086.
Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Suppl 4):iv238-55. https://doi.org/10.1093/annonc/mdy308.
Simmons O, Fetzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther 2017;45(1):169-77. https://doi.org/10.1111/apt.13841.
Esfeh JM, Hajifathalian K, Ansari-Gilani K. Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard. Clin Mol Hepatol 2020;26(1):54-9. https://doi.org/10.3350/cmh.2019.0039.
Singal AG, El-Serag HB. Rational HCC screening approaches for patients with NAFLD. J Hepatol 2022;76(1):195-201. https://doi.org/10.1016/j.jhep.2021.08.028.
Guan MC, Ouyang W, Wang MD, et al. Biomarkers for hepatocellular carcinoma based on body fluids and feces. World J Gastrointest Oncol 2021;13(5):351-65. https://doi.org/10.4251/wjgo.v13.i5.351.
Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract Res Clin Gastroenterol 2014;28(5):843-53. https://doi.org/10.1016/j.bpg.2014.07.018.
Hu B, Tian X, Sun J, et al. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis. Int J Mol Sci 2013;14(12):23559-80. https://doi.org/10.3390/ijms141223559.
Guan MC, Ouyang W, Liu SY, et al. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-Ⅱ, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: a multicenter analysis. Hepatobiliary Pancreat Dis Int 2022;21(6):559-68. https://doi.org/10.1016/j.hbpd.2022.05.003.
Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev 2014;23(1):144-53. https://doi.org/10.1158/1055-9965.EPI-13-0870.
Yang T, Xing H, Wang G, et al. A novel online calculator based on serum biomarkers to detect hepatocellular carcinoma among patients with hepatitis B. Clin Chem 2019;65(12):1543-53. https://doi.org/10.1373/clinchem.2019.308965.
Liu SY, Li C, Sun LY, et al. ASAP Score versus GALAD Score for detection of hepatitis C-related hepatocellular carcinoma: a multicenter case-control analysis. Front Oncol 2022;12:1018396. https://doi.org/10.3389/fonc.2022.1018396.
Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158(7):1999-2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312.
Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69(1):182-236. https://doi.org/10.1016/j.jhep.2018.03.019.
Yang JD, Harmsen WS, Slettedahl SW, et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol 2011;9(7):617-623.e1. https://doi.org/10.1016/j.cgh.2011.03.027.
Yang JD, Kim WR, Coelho R, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011;9(1):64-70. https://doi.org/10.1016/j.cgh.2010.08.019.
Llovet JM, Villanueva A, Marrero JA, et al. Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference. Hepatology 2021;73(Suppl 1):158-91. https://doi.org/10.1002/hep.31327.
Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol 2017;14(4):203-17. https://doi.org/10.1038/nrgastro.2016.193.
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44(3):837-45.
Aby E, Phan J, Truong E, et al. Inadequate hepatocellular carcinoma screening in patients with nonalcoholic steatohepatitis cirrhosis. J Clin Gastroenterol 2019;53(2):142-6. https://doi.org/10.1097/MCG.0000000000001075.
Yip TCF, Lee HW, Chan WK, et al. Asian perspective on NAFLD-associated HCC. J Hepatol 2022;76(3):726-34. https://doi.org/10.1016/j.jhep.2021.09.024.
Berhane S, Toyoda H, Tada T, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol 2016;14(6):875-886.e6. https://doi.org/10.1016/j.cgh.2015.12.042.
Best J, Bechmann LP, Sowa JP, et al. GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2020;18(3):728-735.e4. https://doi.org/10.1016/j.cgh.2019.11.012.
Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis. Hepatology 2019;70(4):1119-33. https://doi.org/10.1002/hep.30702.
Gopal P, Yopp AC, Waljee AK, et al. Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014;12(5):870-7. https://doi.org/10.1016/j.cgh.2013.09.053.
Vipani A, Lauzon M, Luu M, et al. Decreasing trend of serum α-fetoprotein level in hepatocellular carcinoma. Clin Gastroenterol Hepatol 2022;20(5):1177-1179.e4. https://doi.org/10.1016/j.cgh.2021.08.011.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).